FAQs & Fact Sheets: Monoclonal Antibodies

Emergency Use Authorizations [EUA]:

FAQs (Survivor Corps): Monoclonal Antibodies

FDA Update (May 26, 2021): FDA Authorizes 3rd Monoclonal Antibody for Treatment (Sotrovimab)
FDA Update (Apr. 16, 2021): FDA Revokes Monoclonal Antibody EUA for Bamlanivimab -when used alone
*Alternative monoclonal antibody therapies authorized to treat patients with COVID-19 remain available

Regeneron - Casirivimab & Imdevimab:

FAQs from the FDA: EUA for Casirivimab and Imdevimab (when administered together)

• Patient Fact Sheet: Casirivimab / Imdevimab

• Folleto de Datos Para el Paciente: Casirivimab y Imdevimab
  

• Physician EUA Fact Sheet: Casirivimab / Imdevimab (ENG)

Eli Lilly - Bamlanivimab & Etesevimab:

FAQs from the FDA: EUA for Bamlanivimab and Etesevimab (when administered together)

• Patient Fact Sheet: Bamlanivimab / Etesevimab

• Folleto de Datos Para el Paciente: Bamlanivimab y Etesevimab
  

• Physician EUA Fact Sheet: Bamlanivimab / Etesevimab (ENG)

GlaxoSmithKline - Sotrovimab:

FAQs from the FDA: EUA for Sotrovimab

• Patient Fact Sheet: Sotrovimab

• Physician EUA Fact Sheet: Sotrovimab (ENG)